Research Articles | Page 13 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) Jan 2021 Cancer Causes & Control : CCC Myelodysplastic Syndromes (MDS)
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options Jan 2021 Cancer Management and Research Myelodysplastic Syndromes (MDS)
Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Feb 2019 Cancer Med Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium Dec 2020 Cancer Medicine Myelodysplastic Syndromes (MDS)
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Mar 2021 Cancers Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS)
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications Nov 2020 Cells Myelodysplastic Syndromes (MDS)
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes Mar 2019 Clin Lymphoma Myeloma Leuk Myelodysplastic Syndromes (MDS)
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria Jul 2023 Clinical and Experimental Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Considerations for Drug Development in Myelodysplastic Syndromes Jul 2023 Clinical Cancer Research Myelodysplastic Syndromes (MDS)
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes Sep 2019 Clinical Cancer Research: an official Journal of the American Association of Cancer Research Myelodysplastic Syndromes (MDS)